Anticholinergic Toxicity Clinical Trial
Official title:
Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium After Initial Control With Physostigmine (RIVA-AP): a Randomized, Placebo-controlled Trial
Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after initial control with physostigmine. Recent case reports and small observational studies suggest that rivastigmine, which has a longer duration of action than physostigmine, might be useful in the treatment of AMD. In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06447259 -
Drug Burden Index is Associated With Malnutrition in Community-dwelling Dementia Patients
|
||
| Recruiting |
NCT04233541 -
Frailty Status and Increased Risk for Falls
|
||
| Not yet recruiting |
NCT06382649 -
Rivastigmine for Antimuscarinic Delirium
|
Phase 2 |